Ligand Pharmaceuticals, Inc. (LGNDZ) Financials

LGNDZ Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 1.5 billion 534.8 million
Dec. 31, 2025 1.6 billion 543.4 million
Sept. 30, 2025 1.5 billion 526.6 million
June 30, 2025 948.6 million 120.1 million

LGNDZ Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 48.5 million 10.6 million
Dec. 31, 2025 45.8 million 14.3 million
Sept. 30, 2025 13.1 million 14.7 million
June 30, 2025 15.6 million 10.0 million

LGNDZ Net Income
Graph available only for paid members. Upgrade to see it.
DateNet Income
March 31, 2026 -13.3 million
Dec. 31, 2025 44.8 million
Sept. 30, 2025 117.3 million
June 30, 2025 4.8 million

LGNDZ Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 779.4 million 450.9 million -
Dec. 31, 2025 733.5 million 450.4 million -
Sept. 30, 2025 664.5 million 449.9 million 4.4 million
June 30, 2025 245.0 million 4.6 million -

LGNDZ Shares Outstanding

No data available :(

LGNDZ Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 228000 2.1 million 20.8 million -
Dec. 31, 2025 9000 3.5 million 25.0 million -
Sept. 30, 2025 15000 21.0 million 28.4 million -
June 30, 2025 214000 6.6 million 20.2 million -

LGNDZ Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 51.7 million 2.1 million
Dec. 31, 2025 59.7 million 11.1 million
Sept. 30, 2025 115.5 million 11.9 million
June 30, 2025 47.6 million 11.2 million

LGNDZ Revenue by Segment
Graph available only for paid members. Upgrade to see it.

LGNDZ

Price: $0

52 week price:
0.00
0.00

Payout Ratio Range:
-75.58%
86059.68%

Exchange: PNK

Sector: Healthcare

Industry: Medical - Pharmaceuticals

Market Capitalization: 26053

Links: